U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07298330) titled 'A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)' on Dec. 19.
Brief Summary: This is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness of brelovitug compared to delayed treatment.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Hepatitis D Infection
Intervention:
DRUG: Brelovitug 300 mg
Route of administration- Subc...